[go: up one dir, main page]

AR120652A1 - Antagonistas de sstr5 - Google Patents

Antagonistas de sstr5

Info

Publication number
AR120652A1
AR120652A1 ARP200103345A ARP200103345A AR120652A1 AR 120652 A1 AR120652 A1 AR 120652A1 AR P200103345 A ARP200103345 A AR P200103345A AR P200103345 A ARP200103345 A AR P200103345A AR 120652 A1 AR120652 A1 AR 120652A1
Authority
AR
Argentina
Prior art keywords
alkyl
fluoroalkyl
cycloalkyl
membered heterocycloalkyl
halogen
Prior art date
Application number
ARP200103345A
Other languages
English (en)
Inventor
Iyassu Sebhat
Shuwen He
Original Assignee
Kallyope Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kallyope Inc filed Critical Kallyope Inc
Publication of AR120652A1 publication Critical patent/AR120652A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos derivados de diazaespiro[4.5]decano como antagonistas de SSTR5, una composición farmacéutica que comprende a uno de éstos compuestos y el uso de los mismos para el tratamiento de trastornos que implican el eje intestino-cerebro. Reivindicación 1: Un compuesto de la fórmula (1) o una sal, un solvato, un estereoisómero o un profármaco farmacéuticamente aceptable de esta, caracterizado porque: X es -O-, -NR³-, o -C(R⁴)₂-; Y es -C(=O)-, o -S(=O)₂-; Anillo A es arilo, heteroarilo, cicloalquilo o heterocicloalquilo; Anillo B es arilo o heteroarilo; K es -(CH₂)ʲ-G; G es -S(=O)₂OH, -S(=O)OH, o -S(=O)₂NH₂; j es 0 - 4; cada R¹ y R² es independiente hidrógeno, alquilo C₁₋₆ o fluoroalquilo C₁₋₆ o un R¹ y un R² se unen para formar un anillo; R³ es hidrógeno, alquilo C₁₋₆, fluoroalquilo C₁₋₆, o cicloalquilo C₃₋₆; cada R⁴ es independiente hidrógeno, alquilo C₁₋₆ o fluoroalquilo C₁₋₆ o cicloalquilo C₃₋₆. cada RA es independientemente halógeno, -OH, -O-(alquilo C₁₋₆), alquilo C₁₋₆, cicloalquilo C₃₋₆, heterocicloalquilo de 3 a 8 miembros, donde cada alquilo, cicloalquilo y heterocicloalquilo es no sustituido o sustituido por 1, 2, ó 3 sustituyentes seleccionados de halógeno, -CN, -OH, -O-(alquilo C₁₋₆), alquilo C₁₋₆, fluoroalquilo C₁₋₆, hidroxialquilo C₁₋₆, -O-(fluoroalquilo C₁₋₆), cicloalquilo C₃₋₆, heterocicloalquilo de 3 a 6 miembros; cada RB es independientemente halógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆, cicloalquenilo C₃₋₆, heterocicloalquilo de 3 a 8 miembros, heterocicloalquenilo de 3 a 8 miembros, arilo, heteroarilo, -CN, -OR⁹, -OCH₂R⁹, -CO₂R⁹, -CH₂CO₂R⁹, -OC(=O)R⁹, -C(=O)N(R⁹)₂, -N(R⁹)₂, -NR⁹C(=O)R⁹, -NR⁹C(=O)OR¹⁰, -OC(=O)NR⁹, -NR⁹C(=O)N(R⁹)₂, -C(R⁹)=N-OR⁹, -SR⁹, -S(=O)R¹⁰, -S(=O)₂R¹⁰, -S(=O)₂N(R⁹)₂, -P(=O)(OR⁹)₂, -P(=O)(OR⁹)R¹⁰ o -P(=O)(R¹⁰)₂, donde cada alquilo, arilo, y heteroarilo es no sustituido o sustituido por 1, 2 ó 3 sustituyentes seleccionados de halógeno, -CN, -OH, -O-(alquilo C₁₋₆), -CO₂-(alquilo C₁₋₆), alquilo C₁₋₆, fluoroalquilo C₁₋₆, hidroxialquilo C₁₋₆, -O-(fluoroalquilo C₁₋₆), cicloalquilo C₃₋₆, y heterocicloalquilo de 3 a 6 miembros; y donde cada cicloalquilo, cicloalquenilo, heterocicloalquilo y heterocicloalquenilo es no sustituido o sustituido por 1, 2, ó 3 sustituyentes seleccionados de halógeno, -CN, -OH, =O, -O-(alquilo C₁₋₆), alquilo C₁₋₆, fluoroalquilo C₁₋₆, hidroxialquilo C₁₋₆, -O-(fluoroalquilo C₁₋₆), cicloalquilo C₃₋₆, y heterocicloalquilo de 3 a 6 miembros; cada R⁹ es independientemente seleccionado de hidrógeno, alquilo C₁₋₆, fluoroalquilo C₁₋₆, cicloalquilo C₃₋₆, heterocicloalquilo de 3 a 8 miembros, fenilo, y heteroarilo monocíclico, donde cada alquilo, fluoroalquilo, cicloalquilo, heterocicloalquilo, fenilo, y heteroarilo es no sustituido o sustituido por 1, 2, ó 3 sustituyentes seleccionados de halógeno, -CN, -OH, -O-(alquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), -N(alquilo C₁₋₆)₂, alquilo C₁₋₆, fluoroalquilo C₁₋₆, hidroxialquilo C₁₋₆, -O-(fluoroalquilo C₁₋₆), cicloalquilo C₃₋₆, heterocicloalquilo de 3 a 6 miembros, y un resto de fórmula (2); o dos R⁹ en el mismo átomo N se unen junto al átomo N a cual están unidos para formar un heterociclo que contiene N, el cual es no sustituido o sustituido por 1, 2, ó 3 sustituyentes seleccionados de halógeno, -CN, -OH, -O-(alquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), -N(alquilo C₁₋₆)₂, alquilo C₁₋₆, fluoroalquilo C₁₋₆, hidroxialquilo C₁₋₆, -O-(fluoroalquilo C₁₋₆), cicloalquilo C₃₋₆, y heterocicloalquilo de 3 a 6 miembros; cada R¹⁰ es independientemente seleccionado de alquilo C₁₋₆, fluoroalquilo C₁₋₆, cicloalquilo C₃₋₆, heterocicloalquilo de 3 a 8 miembros, fenilo y heteroarilo monocíclico, donde cada alquilo, fluoroalquilo, cicloalquilo, heterocicloalquilo, fenilo y heteroarilo es no sustituido o sustituido con 1, 2 ó 3 sustituyentes seleccionados de halógeno, -CN, -OH, -O-(alquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), -N(alquilo C₁₋₆)₂, alquilo C₁₋₆, fluoroalquilo C₁₋₆, hidroxialquilo C₁₋₆, -O-(fluoroalquilo C₁₋₆), cicloalquilo C₃₋₆, heterocicloalquilo de 3 a 6 miembros, y un resto de fórmula (2); m es 1 ó 2; n es 1 ó 2; p es 0 - 4; y q es 0 - 4.
ARP200103345A 2019-12-03 2020-12-02 Antagonistas de sstr5 AR120652A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962943099P 2019-12-03 2019-12-03

Publications (1)

Publication Number Publication Date
AR120652A1 true AR120652A1 (es) 2022-03-09

Family

ID=76221934

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103345A AR120652A1 (es) 2019-12-03 2020-12-02 Antagonistas de sstr5

Country Status (10)

Country Link
US (3) US20230041621A1 (es)
EP (3) EP4069708A4 (es)
JP (1) JP2023516235A (es)
CN (1) CN115380036A (es)
AR (1) AR120652A1 (es)
AU (1) AU2020398874A1 (es)
CA (1) CA3163243A1 (es)
TW (1) TW202134248A (es)
UY (1) UY38976A (es)
WO (3) WO2021113368A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022550852A1 (en) 2019-10-07 2023-05-03 Kallyope Inc Gpr119 agonists
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
CN116789570B (zh) * 2022-03-14 2026-01-27 长沙理工大学 磺酰胺脱氨制备磺酸衍生物的方法
AU2024242396A1 (en) 2023-03-27 2025-09-04 Scohia Pharma, Inc. Growth hormone secretion promoter
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025222008A1 (en) * 2024-04-19 2025-10-23 Eli Lilly And Company Glucagon receptor agonists and their use as therapies
WO2025222000A1 (en) * 2024-04-19 2025-10-23 Eli Lilly And Company Substituted 1,1'-biphenyl compounds as glucagon receptor agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518376A (ja) * 2001-12-14 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ 化合物およびホルモン感受性リパーゼの活性を低下させるためのその使用
WO2005023809A1 (en) * 2003-09-10 2005-03-17 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
US7709642B2 (en) * 2004-06-25 2010-05-04 Virochem Pharma, Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
WO2007011810A1 (en) * 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
BRPI0715967A2 (pt) * 2006-08-15 2013-08-06 Hoffmann La Roche compostos, processo para a sua manufatura, composiÇÕes farmacÊuticas que os compreendem, mÉtodos para o tratamento e/ou prevenÇço de enfermidades que estço associadas com a modulaÇço de receptores de sst do subtipo 5, e uso destes compostos
AU2007293416A1 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
CA2759651A1 (en) * 2009-05-07 2010-11-11 Merck Sharp & Dohme Corp. Substituted spirocyclic amines useful as antidiabetic compounds
TW201211053A (en) * 2010-05-10 2012-03-16 Nissan Chemical Ind Ltd Spiro compound and drug for activating adiponectin receptor
EP2571356A4 (en) * 2010-05-18 2013-11-20 Merck Sharp & Dohme SPIROISOXAZOLIN COMPOUNDS AS SSTR5 ANTAGONISTS
US8742110B2 (en) * 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
TW201712012A (zh) * 2015-06-16 2017-04-01 美國禮來大藥廠 ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
WO2018024602A1 (en) * 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes

Also Published As

Publication number Publication date
EP4069702A4 (en) 2023-12-27
JP2023516235A (ja) 2023-04-19
EP4073075A1 (en) 2022-10-19
EP4069702A1 (en) 2022-10-12
TW202134248A (zh) 2021-09-16
EP4073075A4 (en) 2023-12-27
CA3163243A1 (en) 2021-06-10
WO2021113368A1 (en) 2021-06-10
AU2020398874A1 (en) 2022-06-23
US20230041621A1 (en) 2023-02-09
CN115380036A (zh) 2022-11-22
EP4069708A1 (en) 2022-10-12
US20230113609A1 (en) 2023-04-13
WO2021113362A1 (en) 2021-06-10
UY38976A (es) 2021-06-30
US20230050965A1 (en) 2023-02-16
WO2021113363A1 (en) 2021-06-10
EP4069708A4 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
AR120652A1 (es) Antagonistas de sstr5
AR110153A1 (es) ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV
AR121669A1 (es) Compuesto de piridazina sustituida
AR120338A1 (es) Piridazinonas como inhibidores de parp7
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR117616A1 (es) Compuestos anti-vih
JP2018526367A5 (es)
AR110346A1 (es) Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
AR103252A1 (es) Compuestos de quinazolina
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR105575A1 (es) COMPUESTOS DE QUINOLINA COMO MODULADORES DE TNFa
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR119657A1 (es) Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AR067060A1 (es) Derivados de guanina policiclicos y sus metodos de uso
AR093504A1 (es) 4-(orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina como inhibidores de cdk9, un intermediario para su sintesis y metodos de obtencion de ambos compuestos
AR097199A1 (es) Inhibidores de rorc2 y sus métodos de uso
AR072301A1 (es) Derivados de acido fenoxicroman carboxilico 6-sustituido utiles en el tratamiento y/o prevencion de enfermedades alergicas e inflamatorias, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos y compuestos intermediarios.
AR117229A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR106297A1 (es) Compuestos macrocíclicos modificados como inhibidores selectivos de la quinasa cdk9
MX379057B (es) Compuestos de benzoxaborol y uso de los mismos.
AR094497A1 (es) Compuestos tetracíclicos sustituidos con tiofeno y métodos de uso de los mismos para el tratamiento de enfermedades víricas

Legal Events

Date Code Title Description
FB Suspension of granting procedure